Jiangsu Lianhuan Pharmaceutical (600513) Stock Overview

Jiangsu Lianhuan Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals, preparations, and API products in China. The company offers clopidogrel bisulfate tablets used to prevent atherothrombotic events; azithromycin tablets for the treatment of mild to moderate infections caused by susceptible strains of designated microorganisms; milrinone injection for short-term intravenous therapy in patients with acute compensated heart failure; and dapoxetine hydrochloride tablets for the treatment of premature ejaculation in men, as well as epulet, ebastine, felodipine, and terfenadine tablets, drotaverine hydrochloride injection, and danazol suppository. It also offers preparation products, which covers urinary system, antihistamines, cardiovascular drugs, steroid hormones, and antibiotics. In addition, the company engages in the wholesale of chemical raw materials and pharmaceuticals, as well as provides technological transfers and technical consultation services. It exports its products to Southeast Asia, North America, South America, Europe, New Zealand, Australia, and other countries. The company was founded in 1999 and is headquartered in Yangzhou, China.